Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor

Bioorganic & Medicinal Chemistry Letters
2009.0

Abstract

ROS1 protein is a receptor tyrosine kinase that has been reported mainly in meningiomas and astrocytomas, and until now, there is no selective inhibitor for this kinase. In this study, we illustrate for the synthesis of a highly potent and selective inhibitor for ROS1 kinase. The synthesized compound 1 was tested initially at a single dose concentration of 10 microM over 45 different kinases. At this concentration, a 94% inhibition of the enzymatic activity of ROS1 kinase was observed, while the inhibition in activity was below 30% in all of the other kinases. The pyrazole compound 1 was further tested in a 10-dose IC(50) mode and showed an IC(50) value of 199 nM for ROS1 kinase. The compound 1 can be used as a promising lead for the development of new selective inhibitors for ROS1 kinase, and it may open the way for new selective therapeutics for astrocytomas.

Knowledge Graph

Similar Paper

Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor
Bioorganic & Medicinal Chemistry Letters 2009.0
Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors
European Journal of Medicinal Chemistry 2012.0
Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors
European Journal of Medicinal Chemistry 2011.0
Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones:  A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases
Journal of Medicinal Chemistry 1998.0
RETRACTED: Design, synthesis, structure–activity relationship and kinase inhibitory activity of substituted 3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ones
Bioorganic & Medicinal Chemistry Letters 2016.0
Discovery and SAR of oxindole–pyridine-based protein kinase B/Akt inhibitors for treating cancers
Bioorganic & Medicinal Chemistry Letters 2006.0
Identification of novel N-(2-aryl-1, 3-thiazolidin-4-one)-N-aryl ureas showing potent multi-tyrosine kinase inhibitory activities
European Journal of Medicinal Chemistry 2018.0
Design, synthesis, and biological evaluation of novel 3-pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives as potent receptor tyrosine kinase inhibitors
Bioorganic & Medicinal Chemistry Letters 2013.0
Synthesis and c-Met Kinase Inhibition of 3,5-Disubstituted and 3,5,7-Trisubstituted Quinolines: Identification of 3-(4-Acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a Novel Anticancer Agent
Journal of Medicinal Chemistry 2011.0
Design, synthesis and biological evaluation of quinazoline SOS1 inhibitors
Bioorganic & Medicinal Chemistry Letters 2023.0